Breaking News Instant updates and real-time market news.

HZNP

Horizon Pharma

$26.43

0.1 (0.38%)

06:14
10/11/19
10/11
06:14
10/11/19
06:14

Piper Jaffray rheumatologist survey favorable for Horizon Pharma

Piper Jaffray analyst David Amsellem says his survey of 25 rheumatologists who are current users of Horizon Pharma's Krystexxa in patients with chronic refractory gout reinforced his view that the rheumatology community's view of the risk/benefit profile of the product "continues to evolve considerably, pointing to greater usage among existing Krystexxa users." The feedback also bodes well for usage of the product among practices that are relatively new to Krystexxa, Amsellem tells investors in a research note. He continues to believe that the combination of "continued aggressive" Krystexxa growth along with contribution from teprotumumab starting next year points to a longer term annual EBITDA growth for Horizon "at least in the high-teens." Amsellem keeps an Overweight rating on the shares with a $33 price target.

  • 11

    Oct

  • 06

    Nov

HZNP Horizon Pharma
$26.43

0.1 (0.38%)

08/14/19
08/14/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Evercore Partners (EVR) upgraded to Neutral from Sell at Goldman Sachs with analyst Richard Ramsden saying believes that stronger U.S. large cap deal activity than he previously expected should support Evercore's revenues. 2. Sanofi (SNY) upgraded to Buy from Neutral at UBS with analyst Laura Sutcliffe saying she sees signs of a turnaround for the company and believes its pipeline can fixed ahead of patent expiration. 3. Bristol-Myers (BMY) upgraded to Overweight from Neutral at Atlantic Equities. 4. Horizon Pharma (HZNP) upgraded to Outperform from Market Perform at BMO Capital with analyst Gary Nachman citing the company's "strong" Q2 results driven by Krystexxa. 5. Ferrari (RACE) upgraded to Buy from Neutral at Goldman Sachs with analyst George Galliers citing the company's Q2 results earlier this month. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/26/19
PIPR
08/26/19
NO CHANGE
Target $33
PIPR
Overweight
Horizon Pharma risk/reward 'highly attractive,' says Piper Jaffray
After conducting a survey of 27 physicians who manage significant numbers of patients with thyroid eye disease, Piper Jaffray analyst David Amsellem reiterates an Overweight rating on Horizon Pharma with a $33 price target. The analyst says the survey reinforced his belief that teprotumumab will over time emerge as a go-to option in a broad swath of moderate-to-severe TED patients. He continues to view Horizon as one of the most attractive longer-term EBITDA growth stories in the broader biopharma space. Amsellem sees a "highly attractive" risk/reward profile at current share levels.
09/11/19
GUGG
09/11/19
INITIATION
GUGG
Buy
Horizon Pharma initiated with a Buy at Guggenheim
Guggenheim analyst Dana Flanders initiated Horizon Pharma with a Buy rating and a $36 price target, calling the company his "Best Idea." The analyst has high confidence in the growth potential of Horizon's drugs Krystexxa and teprotumumab, and believes they will drive upside to margins over the next 3-5 years. Flanders also expects a "strong" tepro launch in Q1 of 2020.
09/26/19
BOFA
09/26/19
INITIATION
Target $34
BOFA
Buy
Horizon Pharma initiated with a Buy at BofA/Merrill
BofA/Merrill analyst Jason Gerberry initiated Horizon Pharma with a Buy rating and a price target of $34. The analyst contends that the stock can generate multiple expansion from its tepro approval and favorable payer coverage for thyroid eye disease as well as from the continued execution of Krystexxa re-launch and the "read-across to tepro launch hurdles".

TODAY'S FREE FLY STORIES

SAP

SAP

$129.13

0.55 (0.43%)

05:38
10/21/19
10/21
05:38
10/21/19
05:38
Earnings
SAP reports Q3 non-IFRS EPS EUR 1.30 vs. EUR 1.14 last year »

Reports Q3 revenue EUR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 19

    Nov

DANOY

Danone

$0.00

(0.00%)

05:32
10/21/19
10/21
05:32
10/21/19
05:32
Downgrade
Danone rating change  »

Danone downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

JBAXY

Julius Baer

$0.00

(0.00%)

05:30
10/21/19
10/21
05:30
10/21/19
05:30
Downgrade
Julius Baer rating change  »

Julius Baer downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHR

Danaher

$138.08

0.31 (0.23%)

05:28
10/21/19
10/21
05:28
10/21/19
05:28
Hot Stocks
Danaher to sell certain businesses to Sartorius AG for $750M »

Danaher announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 07

    Nov

SAP

SAP

$129.13

0.55 (0.43%)

, MSFT

Microsoft

$137.34

-2.34 (-1.68%)

05:26
10/21/19
10/21
05:26
10/21/19
05:26
Hot Stocks
SAP enters go-to-market partnership with Microsoft »

SAP (SAP) and Microsoft…

SAP

SAP

$129.13

0.55 (0.43%)

MSFT

Microsoft

$137.34

-2.34 (-1.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 23

    Oct

  • 26

    Oct

  • 27

    Oct

  • 29

    Oct

  • 06

    Nov

  • 19

    Nov

  • 21

    Nov

ALSMY

Alstom

$0.00

(0.00%)

05:26
10/21/19
10/21
05:26
10/21/19
05:26
Downgrade
Alstom rating change  »

Alstom downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DANOY

Danone

$0.00

(0.00%)

05:25
10/21/19
10/21
05:25
10/21/19
05:25
Downgrade
Danone rating change  »

Danone downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

HON

Honeywell

$165.61

-1.87 (-1.12%)

05:24
10/21/19
10/21
05:24
10/21/19
05:24
Hot Stocks
Honeywell sees 7,600 new business jet deliveries over next decade »

The business jet industry…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$344.09

-25.04 (-6.78%)

05:23
10/21/19
10/21
05:23
10/21/19
05:23
Downgrade
Boeing rating change  »

Boeing downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

IRT

Independence Realty Trust

$15.03

(0.00%)

05:22
10/21/19
10/21
05:22
10/21/19
05:22
Downgrade
Independence Realty Trust rating change  »

Independence Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

RHHBY

Roche

$0.00

(0.00%)

05:21
10/21/19
10/21
05:21
10/21/19
05:21
Hot Stocks
Genentech says Phase III IMbrave150 study met co-primary endpoints »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Nov

  • 06

    Nov

  • 08

    Nov

  • 11

    Nov

  • 12

    Nov

  • 07

    Dec

PINS

Pinterest

$25.30

-0.7 (-2.69%)

05:21
10/21/19
10/21
05:21
10/21/19
05:21
Upgrade
Pinterest rating change  »

Pinterest upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 19

    Nov

COMM

CommScope

$11.56

-0.06 (-0.52%)

05:20
10/21/19
10/21
05:20
10/21/19
05:20
Upgrade
CommScope rating change  »

CommScope upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 07

    Nov

  • 09

    Dec

MFGP

Micro Focus

$15.13

0.56 (3.84%)

, OTEX

OpenText

$39.30

-1.545 (-3.78%)

05:18
10/21/19
10/21
05:18
10/21/19
05:18
Recommendations
Micro Focus, OpenText analyst commentary  »

Micro Focus could attract…

MFGP

Micro Focus

$15.13

0.56 (3.84%)

OTEX

OpenText

$39.30

-1.545 (-3.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 06

    Nov

  • 19

    Nov

MSFT

Microsoft

$137.34

-2.34 (-1.68%)

, CRM

Salesforce

$144.18

-1.995 (-1.36%)

05:15
10/21/19
10/21
05:15
10/21/19
05:15
Recommendations
Microsoft, Salesforce, Intuit, SailPoint, Zuora, Varonis analyst commentary  »

High growth software…

MSFT

Microsoft

$137.34

-2.34 (-1.68%)

CRM

Salesforce

$144.18

-1.995 (-1.36%)

INTU

Intuit

$262.54

-4.03 (-1.51%)

SAIL

SailPoint

$18.32

-0.34 (-1.82%)

ZUO

Zuora

$13.63

-0.5 (-3.54%)

VRNS

Varonis

$62.36

-1.56 (-2.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 26

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 19

    Nov

  • 21

    Nov

  • 16

    Dec

XLRN

Acceleron

$42.16

-1.02 (-2.36%)

05:09
10/21/19
10/21
05:09
10/21/19
05:09
Recommendations
Acceleron analyst commentary  »

Piper sees near-term…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 07

    Dec

  • 04

    Apr

TLSNF

Telia

$0.00

(0.00%)

05:04
10/21/19
10/21
05:04
10/21/19
05:04
Downgrade
Telia rating change  »

Telia downgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALRM

Alarm.com

$47.23

-0.5 (-1.05%)

05:01
10/21/19
10/21
05:01
10/21/19
05:01
Upgrade
Alarm.com rating change  »

Alarm.com upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

  • 13

    Nov

  • 09

    Dec

SWAV

ShockWave Medical

$32.30

-0.29 (-0.89%)

04:59
10/21/19
10/21
04:59
10/21/19
04:59
Initiation
ShockWave Medical initiated  »

ShockWave Medical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

APLS

Apellis

$27.78

-0.03 (-0.11%)

04:55
10/21/19
10/21
04:55
10/21/19
04:55
Conference/Events
Apellis participates in a conference call with JPMorgan »

SMid Biotechnology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 07

    Dec

FPRX

Five Prime

$3.98

-0.11 (-2.69%)

04:55
10/21/19
10/21
04:55
10/21/19
04:55
Conference/Events
Five Prime management to meet with Wedbush »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

ADAP

Adaptimmune

$0.96

-0.035 (-3.54%)

04:55
10/21/19
10/21
04:55
10/21/19
04:55
Conference/Events
Adaptimmune management to meet with Mizuho »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 23

    Oct

ALDR

Alder Biopharmaceuticals

$18.92

0.02 (0.11%)

04:55
10/21/19
10/21
04:55
10/21/19
04:55
Conference/Events
Alder Biopharmaceuticals management to meet with Mizuho »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 21

    Feb

04:55
10/21/19
10/21
04:55
10/21/19
04:55
General news
Breaking General news story  »

3-Month Bill Auction to…

04:55
10/21/19
10/21
04:55
10/21/19
04:55
General news
Breaking General news story  »

6-Month Bill Auction to…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.